St John's Laboratory has a selection of loading controls for western blot and other applications that cover a wide range of molecular weight proteins suitable for users' experiments.
GeneTex offers an extensive collection of high-quality antibodies for research of the central nervous system.
AdipoGen develops recombinant monoclonal antibodies (RecMAbs) without the use of animals. The antibodies are created using an in vitro technology, antibody phage display — an alternative to the hybridoma technology that circumvents the limitations of the immune system.
Absolute Antibody's murine bispecific reagents enable researchers and drug developers to more easily evaluate potential bispecific combinations in mouse models.
The Anti-Alpaca secondary antibody product line targets the IgG repertoire of camelid immunoglobulins, including whole molecule, subclass and VHH domain specificities. They are raised against alpaca and cross-react with llama.
Scientists have developed a new antibody technology that combines the advantages of antibody-based therapies with the convenience of oral drug administration.
Leica Biosystems' PD-L1 BOND antibody is designed for use on their fully automated BOND IHC and ISH staining platform.
The scientific community is currently facing a reproducibility crisis. Over 70% of researchers are failing to reproduce published experiments.
Biotechnology company IONTAS has announced a panel of human antibodies that neutralise elements of black mamba snake toxin in an in vivo model.
Bio-Rad Laboratories has launched a range of recombinant monoclonal anti-ranibizumab antibodies that are highly specific for the monoclonal antibody drug ranibizumab (Lucentis) or the complex of ranibizumab with its target, vascular endothelial growth factor A (VEGF-A).
Thermo Fisher Scientific will utilise BenchSci's machine learning platform to mine antibody data published in peer-reviewed scientific journals.
The Native Antigen Company is an expert in the production of bacterial and viral antigens, specialising in the development and manufacture of native and recombinant viral and bacterial antigens.
Bio-Rad Laboratories has launched a range of anti-idiotypic antibodies targeting the immune checkpoint inhibitor drugs pembrolizumab (Keytruda) and nivolumab (Opdivo). Anti-pembrolizumab and anti-nivolumab antibodies are designed for use in bioanalytical assays to monitor the drug levels in cancer patients.
Bio-Rad's anti-vedolizumab antibodies include four recombinant monoclonal anti-idiotypic antibodies that are highly specific for the humanised IgG1 kappa antibody drug vedolizumab, and are suitable for development of bioanalytical and patient monitoring assays.
Bio-Rad Laboratories has announced the StarBright Blue 520 Fluorescent Secondary Antibodies — fluorescent dye-labelled secondary antibodies for use in multiplex western blotting.